| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(13 years from now) | |
| US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
| US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
Carospir is owned by Cmp Dev Llc.
Carospir contains Spironolactone.
Carospir has a total of 8 drug patents out of which 0 drug patents have expired.
Carospir was authorised for market use on 04 August, 2017.
Carospir is available in suspension;oral dosage forms.
Carospir can be used as carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; carospir is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents; carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction, carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure.
The generics of Carospir are possible to be released after 28 October, 2036.
Drugs and Companies using SPIRONOLACTONE ingredient
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; C...
Dosage: SUSPENSION;ORAL
CAROSPIR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic